A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find optimistic dose and to evaluate the efficacy and safety of SK-PC-B70M in patients with mild to moderate Alzheimer's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: SK Chemicals Co., Ltd.; SK Chemicals Co.,Ltd.

Criteria

Inclusion Criteria:

• Age range : 50 ~ 85 years

• Clinical diagnosis of probable Alzheimer's disease (DSM-IV and NINCDS-ADRDA criteria)

• MRI within the last 12 months consistent with a diagnosis of AD

• MMSE score 10 to 26

• AChEI or memantine was discontinued at least 3 months prior to screening

Exclusion Criteria:

• Patient in mild cognitive impairment (MCI; CDR-SB <2.5)

• Other central nervous disease

• hypothyroidism, Vitamin B12/ Folic acid deficiency, hypercalcemia, neurosyphilis, AIDS

• T.I.A or Major infarction within the last 12 months

• Any serious disorder that could limit the ability of the patient to participate in the study

• COPD or asthma

• Any condition which would make the patient or the caregiver, in the opinion of the investigator, unsuitable for the study